Personalized Translational Platform for Biomarker Discovery in Brain Tumors
| Status: | Completed |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 85 |
| Updated: | 8/30/2017 |
| Start Date: | December 2009 |
| End Date: | March 2016 |
The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue)
biomarkers will better predict early brain tumor response to treatments and will be more
reliable prognostic markers in patients with malignant brain tumors.
biomarkers will better predict early brain tumor response to treatments and will be more
reliable prognostic markers in patients with malignant brain tumors.
Inclusion Criteria:
- Newly diagnosed or suspected high grade glioma ≥ 1cm in diameter on postoperative
anatomic imaging (contrast MRI), prior to initiation of chemoXRT
- Anticipated survival ≥6 months
- Able to give informed consent
- Capable of undergoing MRI and PET scans without the need for sedation or general
anesthesia
- Male or Female
Exclusion Criteria:
- Prior radiation therapy and chemotherapy to the brain
- Active intracranial infection or nonglial brain mass.
- Recent large intracranial hemorrhage (<1 month)
- Expected survival <6 months
- Pregnant or nursing
- Renal failure
- Lives far from BWH and/or is unwilling/ unable to return for scheduled imaging visits.
We found this trial at
2
sites
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
Click here to add this to my saved trials
Click here to add this to my saved trials